Panome Bio is a technology company.
Panome Bio has raised $6.0M across 1 funding round.
Panome Bio has raised $6.0M in total across 1 funding round.
Panome Bio has raised $6.0M in total across 1 funding round.
Panome Bio's investors include Telegraph Hill Partners.
Panome Bio is a St. Louis-based life sciences company specializing in multi-omics services, including next-generation metabolomics, proteomics, lipidomics, and integrated analysis for biomarker discovery and drug development.[1][2][3] It serves pharmaceutical, biotech, and research organizations by providing untargeted mass spectrometry-based workflows that profile metabolites, proteins, and other biomolecules to uncover metabolic fingerprints, disease mechanisms, and drug responses, addressing limitations in traditional targeted approaches.[2][4] Launched with a $6M Series A in 2022, the company demonstrates strong growth through expansions like phosphoproteomics and transcriptomics services, enabling deeper insights into cancer, aging, and bioreactor optimization.[1][3][5]
Panome Bio emerged from technology developed by Chief Scientific Officer Dr. Gary Patti, whose Next-Generation Metabolomics platform was incubated by BioGenerator, a St. Louis venture builder.[1] Founded in 2022 and headquartered in Saint Louis, Missouri, the company launched with $6M in Series A financing led by BioGenerator Ventures to scale operations, expand labs, and grow its team.[1][3] CEO Edward Weinstein has highlighted the platform's ability to deliver a global metabolite view, driving early traction with biopharma clients seeking advanced biomarker discovery.[1] Pivotal moments include rapid service expansions, such as adding transcriptomics in 2025 and global phosphoproteomics for analyzing protein phosphorylation in disease pathways.[3][5]
Panome Bio stands out in the multi-omics space through proprietary technologies and workflows that outperform legacy methods:
Panome Bio rides the multi-omics revolution in precision medicine and biotech R&D, where integrating metabolomics, proteomics, and beyond reveals phenotype closest to disease—critical as targeted assays fall short on dynamic range and novelty.[1][2][4] Timing aligns with surging demand for untargeted data in oncology, aging, drug metabolism, and cultivated meat bioprocessing, fueled by mass spec advances like Orbitrap Astral and AI bioinformatics.[5][6] Market forces favoring Panome include biopharma's push for biomarkers amid clinical trial failures (e.g., signaling pathway insights for resistance) and the $10B+ omics services sector's shift to integrated platforms.[3][5] It influences the ecosystem by democratizing high-depth analysis for startups and pharma, accelerating discoveries from lab to trials.[1][6]
Panome Bio is poised for accelerated growth by layering services like phosphoproteomics and transcriptomics atop its core metabolomics-proteomics engine, targeting expanding applications in cultivated biotech and clinical translation.[3][5][6] Trends like AI-driven omics integration and single-sample multi-profiling will amplify its edge, potentially capturing share from fragmented providers amid rising bioreactor and personalized medicine needs. Its influence may evolve into a go-to platform for phenotype-driven drug discovery, scaling via partnerships and further funding to redefine biopharma workflows—building directly on its launch promise of unparalleled biomolecule access.[1][2]
Panome Bio has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $6.0M Series A | Telegraph Hill Partners |